Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis
Open Access
- 14 March 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1323366
Abstract
In 2020, bladder cancer, which commonly presents as urothelial carcinoma, became the 10th most common malignancy. For patients with metastatic urothelial carcinoma, the standard first-line treatment remains platinum-based chemotherapy, with immunotherapy serving as an alternative in cases of programmed death ligand 1 expression. However, treatment options become limited upon resistance to platinum and programmed death 1 or programmed death ligand 1 agents. Since the FDA’s approval of Enfortumab Vedotin and Sacituzumab Govitecan, the therapeutic landscape has expanded, heralding a shift towards antibody–drug conjugates as potential first-line therapies. Our review employed a robust scientometric approach to assess 475 publications on antibody–drug conjugates in urothelial carcinoma, revealing a surge in related studies since 2018, predominantly led by U.S. institutions. Moreover, 89 clinical trials were examined, with 36 in Phase II and 13 in Phase III, exploring antibody–drug conjugates as both monotherapies and in combination with other agents. Promisingly, novel targets like HER-2 and EpCAM exhibit substantial therapeutic potential. These findings affirm the increasing significance of antibody–drug conjugates in urothelial carcinoma treatment, transitioning them from posterior-line to frontline therapies. Future research is poised to focus on new therapeutic targets, combination therapy optimization, treatment personalization, exploration of double antibody-coupled drugs, and strategies to overcome drug resistance.Keywords
This publication has 160 references indexed in Scilit:
- Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinomaCancer Medicine, 2023
- HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world studyCancer Immunology, Immunotherapy, 2023
- Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cellsCytometry Part B: Clinical Cytometry, 2020
- Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successesJournal of Cellular Physiology, 2018
- A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activityBreast Cancer Research and Treatment, 2015
- Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug ConjugatesPharmaceutical Research, 2015
- Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenograftsInternational Journal of Cancer, 2015
- Evolving Strategies for Target Selection for Antibody-Drug ConjugatesPharmaceutical Research, 2015
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Cancer and Metastasis Reviews, 2012
- Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinomaInternational Journal of Cancer, 2004